MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-22-2025
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.41 B |
Market Cap[1] |
$ 501 B |
EBITDA (LTM) |
$ 9.42 B |
P/E (LTM) |
20.47 |
P/S (LTM) |
5.42 |
EPS (LTM) |
10.13 |
Johnson & Johnson is a multinational corporation that specializes in healthcare products, medical devices, and pharmaceuticals. Founded in 1886, the company has grown to become one of the largest healthcare companies in the world, with operations in over 60 countries.
The company's products are used by millions of people every day, from baby shampoo and band-aids to prescription drugs and surgical equipment. Some of its most well-known brands include Tylenol, Neutrogena, and Listerine.
Johnson & Johnson is committed to improving the health and well-being of people around the world. The company invests heavily in research and development, with a focus on finding new treatments for diseases such as cancer, Alzheimer's, and HIV/AIDS.
In addition to its healthcare products, Johnson & Johnson is also known for its commitment to corporate social responsibility. The company has a long history of supporting various charitable causes, including disaster relief efforts and global health initiatives.
Overall, is a trusted and respected leader in the healthcare industry, with a strong track record of innovation and social responsibility.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.87 | 11.68 % | $ 477 M | Nasdaq Global Select Market |  Britain |
 |
Aclaris Therapeutics
ACRS
|
$ 3.0 | -0.99 % | $ 232 M | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.1 | -0.64 % | $ 7.46 B | Nasdaq Capital Market |  Australia |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aptorum Group Limited
APM
|
$ 1.1 | -3.51 % | $ 6 M | Nasdaq Global Select Market |  China |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 211.15 | 1.04 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
BioVie
BIVI
|
$ 1.22 | 0.83 % | $ 1.8 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.17 | -18.84 % | $ 370 M | NYSE American |  Israel |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 95.17 | 0.69 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Catalyst Biosciences
CBIO
|
$ 12.12 | -1.86 % | $ 798 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 26.86 | -0.96 % | $ 1.3 B | Nasdaq Global Select Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Anika Therapeutics
ANIK
|
$ 9.53 | -0.21 % | $ 140 M | Nasdaq Global Select Market,SPB | USA |
 |
Certara
CERT
|
$ 8.85 | -0.45 % | $ 1.42 B | Nasdaq Global Select Market | USA |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
Cellectis S.A.
CLLS
|
$ 4.95 | 4.2 % | $ 116 M | Nasdaq Global Market | France |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 583.1 | -0.13 % | $ 44.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Aytu BioScience
AYTU
|
$ 2.55 | 4.08 % | $ 16 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 92.68 | -0.24 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Burford Capital Limited
BUR
|
$ 9.25 | 1.82 % | $ 1.49 B | NYSE | Britain |
 |
Celldex Therapeutics
CLDX
|
$ 25.93 | -1.8 % | $ 1.67 M | Nasdaq Global Select Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.43 | 2.65 % | $ 739 M | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.